| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_397384a6d230e34cf9e18e9c7d9b0a03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d33087dfb06f23a561b692aecc073feb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4712
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6878
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5308
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56977
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6887 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2017-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c066d2c17f7e850a6399459ad5b256c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3936e8828c524fccb503a2cfa15b738
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99e661df1f4f52ea9728e60283c9b5ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85291e54594a786dfc8873d40820555e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c9d4c64ba4efe4b6855c7fd2a7ada9d |
| publicationDate |
2021-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2826480-T3 |
| titleOfInvention |
Methods to predict the usefulness of neoantigens for immunotherapy |
| abstract |
A method for predicting the utility of a cancer-associated neoantigen or a neoepitope thereof comprising one or more cancer-specific amino acid modifications for anticancer immunotherapy, the method comprising determining the distribution or location of the neoantigen comprising determining in a database computing whether the neoantigen is localized or abundant in the cytosol and / or within exosomes in vivo, wherein the location or abundance of the neoantigen or a nucleic acid that encodes it, or a neoepitope of the neoantigen in the cytosol and / or within exosomes in vivo indicates that the neoantigen or neoepitope thereof is useful for immunotherapy against cancer, in which the processing and presentation of the neoantigen in the MHC I pathway results in the recognition of complexes formed by MHC I and neoepitopes of the neoantigen by CD8 + T cells. |
| priorityDate |
2016-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |